Truist Financial Forecasts Strong Price Appreciation for Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences (NYSE:EW) had its target price increased by stock analysts at Truist Financial from $90.00 to $95.00 in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The brokerage presently has a “hold” rating on the medical research company’s stock. Truist Financial’s target price indicates a potential upside of 10.82% from the company’s current price.

A number of other brokerages also recently weighed in on EW. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. TD Cowen restated a “buy” rating and issued a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Robert W. Baird boosted their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Mizuho increased their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Royal Bank Of Canada raised their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $98.95.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $85.72 on Thursday. The firm has a market cap of $49.36 billion, a price-to-earnings ratio of 45.60, a PEG ratio of 2.20 and a beta of 0.86. Edwards Lifesciences has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The company’s 50 day moving average is $87.34 and its 200 day moving average is $83.94.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the business earned $0.64 earnings per share. Edwards Lifesciences’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 45,577 shares of company stock valued at $3,855,527. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of EW. Investors Research Corp raised its stake in shares of Edwards Lifesciences by 855.3% in the second quarter. Investors Research Corp now owns 898 shares of the medical research company’s stock worth $81,000 after purchasing an additional 804 shares during the last quarter. Handelsbanken Fonder AB boosted its position in Edwards Lifesciences by 22.0% in the second quarter. Handelsbanken Fonder AB now owns 1,541,212 shares of the medical research company’s stock valued at $139,418,000 after buying an additional 278,208 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors boosted its position in Edwards Lifesciences by 37.1% in the second quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 7,208 shares of the medical research company’s stock valued at $652,000 after buying an additional 1,950 shares during the last quarter. Revolve Wealth Partners LLC acquired a new position in Edwards Lifesciences in the 2nd quarter worth approximately $206,000. Finally, Everpar Advisors LLC acquired a new position in Edwards Lifesciences in the 2nd quarter worth approximately $267,000. 79.46% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.